

# QUANTITY LIMIT PRIOR AUTHORIZATION CRITERIA

DRUG CLASS	COMBINATION ACNE TOPICAL PRODUCTS
BRAND NAME (generic)	
	<b>ACANYA</b> (clindamycin phosphate-benzoyl peroxide gel)
	<b>BENZACLIN</b> (clindamycin phosphate-benzoyl peroxide gel)
	<b>BENZAMYCIN</b> (erythromycin/benzoyl peroxide gel)
	<b>CABTREO</b> (clindamycin phosphate-adapalene-benzoyl peroxide gel)
	(clindamycin phosphate-benzoyl peroxide gel, Neuac gel) (generic Duac)
	<b>ONEXTON</b> (clindamycin phosphate-benzoyl peroxide gel)

**Status: CVS Caremark® Criteria**

**Type: Quantity Limit; Post Limit Prior Authorization**

## POLICY

### FDA-APPROVED INDICATIONS

#### **Acanya**

Acanya Gel is indicated for the topical treatment of acne vulgaris in patients 12 years or older.

#### **BenzaClin**

BenzaClin Topical Gel is indicated for the topical treatment of acne vulgaris.

#### **Benzamycin**

Benzamycin Topical Gel is indicated for the topical treatment of acne vulgaris.

#### **Cabtreo**

Cabtreo is indicated for the topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older.

#### **Clindamycin Phosphate-Benzoyl Peroxide Gel 1.2% / 5%, Neuac**

Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2% / 5% is indicated for the topical treatment of inflammatory acne vulgaris in patients 12 years and older.

#### **Onexton**

Acne Products Combinations Topical Limit, Post PA Policy UDR 08-2023 v2.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2023 CVS Health and/or its affiliates. All rights reserved. 106-58428J 021423

Onexton (clindamycin phosphate and benzoyl peroxide) Gel, 1.2% / 3.75% is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.

## **INITIAL QUANTITY LIMIT\*\***

### **INITIAL LIMIT QUANTITY**

Limits should accumulate across same chemical entity up to highest quantity listed depending on the order the claims are processed. Accumulation does not apply if limit is coded for daily dose.

PLEASE NOTE: Since manufacturer package sizes may vary, it is the discretion of the dispensing pharmacy to fill quantities per package size up to these quantity limits. In such cases the filling limit and day supply may be less than what is indicated.

<b>Drug</b>	<b>1 Month Limit*</b>	<b>3 Month Limit*</b>
Acanya (clindamycin phosphate-benzoyl peroxide gel)	50 grams / 25 days	150 grams / 75 days
BenzaClin (clindamycin phosphate-benzoyl peroxide gel)	50 grams / 25 days	150 grams / 75 days
Benzamycin (erythromycin-benzoyl peroxide gel)	47 grams / 25 days	141 grams / 75 days
Cabtreo (clindamycin phosphate-adapalene-benzoyl peroxide gel)	50 grams / 25 days	150 grams / 75 days
clindamycin phosphate-benzoyl peroxide gel, 1.2%-5%, Neuac	45 grams / 25 days	135 grams / 75 days
Onexton (clindamycin phosphate-benzoyl peroxide gel)	50 grams / 25 days	150 grams / 75 days

*\*The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.*

\*\*If the patient is requesting more than the initial quantity limit, the claim will reject with a message indicating that a prior authorization is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

## **COVERAGE CRITERIA**

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for the topical treatment of acne vulgaris
- AND**
  - The request is NOT for continuation of therapy
- OR**
  - The request is for continuation of therapy
- AND**
  - The patient has achieved or maintained a positive clinical response as evidenced by improvement (e.g., reduction in number of lesions, etc.)

Quantity Limits apply.

## **POST LIMIT QUANTITY**

PLEASE NOTE: Since manufacturer package sizes may vary, it is the discretion of the dispensing pharmacy to fill quantities per package size up to these quantity limits. In such cases the filling limit and day supply may be less than what is indicated.

<b>Medication</b>	<b>1 Month Limit*</b>	<b>3 Month Limit*</b>
Acanya (clindamycin phosphate-benzoyl peroxide gel)	100 grams / 25 days	300 grams / 75 days
BenzaClin (clindamycin phosphate-benzoyl peroxide gel)	100 grams / 25 days	300 grams / 75 days
Benzamycin (erythromycin-benzoyl peroxide gel)	94 grams / 25 days	282 grams / 75 days
Cabtreo (clindamycin phosphate-adapalene-benzoyl peroxide gel)	100 grams / 25 days	300 grams / 75 days
clindamycin phosphate-benzoyl peroxide gel, 1.2%-5%, Neuac	90 grams / 25 days	270 grams / 75 days
Onexton (clindamycin phosphate-benzoyl peroxide gel)	100 grams / 25 days	300 grams / 75 days

\* The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.

Duration of Approval (DOA):

- 4651-HJ: Initial therapy DOA: 4 months; Continuation of therapy DOA: 12 months

## **REFERENCES**

1. Benzamycin [package insert]. Bridgewater, NJ: Bausch Health US, LLC; November 2020.
2. Acanya [package insert]. Bridgewater, NJ: Bridgewater, NJ: Bausch Health US, LLC; September 2020.
3. BenzaClin [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; February 2017.
4. Cabtreo [package insert]. Bridgewater, NJ: Bausch Health US, LLC; October 2023.
5. Clindamycin Phosphate-Benzoyl Peroxide Gel, 1.2% / 5% [package insert]. Princeton, NJ: Sandoz Inc.; October 2019.
6. Onexton [package insert]. Bridgewater, NJ: Bausch Health US, LLC; April 2020.
7. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed June 13, 2023.
8. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 06/13/2023).
9. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of Care for the Management of Acne Vulgaris. *J Am Acad Dermatol*. 2016;74(5):945-977.e33.
10. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of Care for the Management of Atopic Dermatitis Section 2. Management and Treatment of Atopic Dermatitis with Topical Therapies. *J Am Acad Dermatol*. 2014;71(1):116-132.
11. Elmetts CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriasis with Topical Therapy and Alternative Medicine Modalities for Psoriasis Severity Measures. *J Am Acad Dermatol*. 2021;84(2):432-470.
12. Burn Triage and Treatment - Thermal Injuries. Available at: <https://chemm.hhs.gov/burns.htm>. Accessed June 13, 2023.